Spinal Stabilization Technologies™ Announces Enrollment of First U.S. Patient in IDE Trial for PerQdisc™ Nucleus Replacement Device
Summary
This event marks the beginning of SSTs U.S.-based trial to evaluate its PerQdisc system for patients suffering from degenerative disc disease (DDD).The reduction in pain and overall clinical outcomes observed with PerQdisc during the feasibility trials (over 40 patients treated) have been exceptional, stated Dr. Pierce Nunley, Principal Investigator and Medical Director of the Spine Institute of Louisiana. SSTs PerQdisc is a breakthrough alternative that avoids fusion and leaves the surrounding anatomy intact.To support the trial and accelerate its path toward regulatory approval, SST recently raised $17 million in funding from existing and new investors. This investment underscores confidence in SSTs technology and will be used to advance the IDE trial and further clinical development initiatives.SST is also pleased to announce the appointment of Dr. Frank Phillips to its Board of Directors. His expertise and leadership in the field of spinal surgery will be instrumental in guiding SSTs strategic direction and clinical adoption, commented Mark Novotny, CEO of SST.This is an exciting time for SST as we expand our clinical research into the U.S. market, said Novotny, With strong clinical results, a highly experienced team, and the addition of Dr. Phillips to our Board, we are well-positioned to bring PerQdisc to patients in need of better treatment options.About Spinal Stabilization TechnologiesSpinal Stabilization Technologies, LLC (SST) is a medical technology company in the U.S. focused on developing innovative solutions for patients suffering from lumbar discogenic back pain. With a strong commitment to evidence-based medicine, SST has built a robust intellectual property portfolio and is dedicated to advancing the field of spine surgery with minimally invasive technologies.